Sign inCreate account

Report workspace

Add to folder
NCT05925920COMPLETEDanonymous

A First in Human, Single Center, Single Dose, Randomized, Placebo-controlled, Dose, Escalating Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered ENT-03S for the Treatment of Obesity and Diabetes

Sponsor

Source record

Metabolics Pharma

Phase

Source record

Phase 1

Modality

AI-normalized

small molecule

Target

AI-normalized

Not specified in the provided data; further investigation required to determine the precise molecular or mechanistic target profile of ENT-03S.

Indication / condition

AI-normalized

Obesity

Intervention

Source record

ENT-03, Placebo

Source & freshness

Source record

NCT ID

NCT05925920

Original source

ClinicalTrials.gov

Source last updated

Jun 01, 2026

Ingested at

Jun 13, 2026

Internal sync

Jun 13, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT05925920

Title

A First in Human, Single Center, Single Dose, Randomized, Placebo-controlled, Dose, Escalating Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered ENT-03S for the Treatment of Obesity and Diabetes

Sponsor

Metabolics Pharma

Status

COMPLETED

Phase

Phase 1

Condition raw

Obesity, Diabetes Mellitus, Type 2

Condition normalized

Obesity, Diabetes Mellitus, Type 2

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Not specified in the provided data; further investigation required to determine the precise molecular or mechanistic target profile of ENT-03S.

Target normalized

Not specified in the provided data; further investigation required to determine the precise molecular or mechanistic target profile of ENT-03S.

Interventions

ENT-03, Placebo

Public preview

Source record

Metabolics Pharma's ENT-03S is positioned to address significant unmet needs in the obesity and Type 2 diabetes markets, which are characterized by a growing prevalence and limited effective treatment options. The trial's design, focusing on safety, tolerability, pharmacokinetics, and pharmacodynamics, suggests a strategic approach to mitigate risks associated with early-stage development. The competitive landscape includes established players with existing therapies, necessitating a robust differentiation strategy for ENT-03S. Successful outcomes could enhance Metabolics Pharma's market positioning and attract potential partnerships or acquisition interest, particularly if the drug demonstrates favorable efficacy and safety profiles.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A First in Human, Single Center, Single Dose, Randomized, Placebo-controlled, Dose, Escalating Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered ENT-03S for the Treatment of Obesity and Diabetes

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 16, 2026

NCT ID

NCT05925920

Status

COMPLETED

Phase

Phase 1

Sponsor

Metabolics Pharma

Executive brief

Investment-Ready Snapshot

Metabolics Pharma's ENT-03S is positioned to address significant unmet needs in the obesity and Type 2 diabetes markets, which are characterized by a growing prevalence and limited effective treatment options. The trial's design, focusing on safety, tolerability, pharmacokinetics, and pharmacodynamics, suggests a strategic approach to mitigate risks associated with early-stage development. The competitive landscape includes established players with existing therapies, necessitating a robust differentiation strategy for ENT-03S. Successful outcomes could enhance Metabolics Pharma's market positioning and attract potential partnerships or acquisition interest, particularly if the drug demonstrates favorable efficacy and safety profiles.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJun 01, 2026
Internal syncJun 13, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05925920

Indication

Obesity

Modality

small molecule

Target

Not specified in the provided data; further investigation required to determine the precise molecular or mechanistic target profile of ENT-03S.

Intervention

ENT-03, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.